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ABSTRACT
The purpose of this study was to examine the effects of smoking on risk factors
associated with cardiovascular disease (CVD) and determine the efficacy of antioxidant-rich
berries in ameliorating these risk factors in postmenopausal smokers. Menopause and cigarette
smoking have been identified as major risk factors for CVD due to a decrease in antioxidant
protection, increase in inflammation and oxidative stress, and adverse changes in serum lipids.
Antioxidants, specifically flavonoid compounds found in blackberries and blueberries, have been
shown to prevent low-density lipoprotein cholesterol oxidation and thus prevent downstream
inflammation and oxidative stress. Healthy, postmenopausal nonsmokers (n=14) and smokers
(n=31) were recruited to participate in the three-month study and smokers were randomly
assigned to one of three groups: smoker control (n=12), smoker + 45 g/day freeze-dried
blackberries (n=6), or smoker + 45 g/day freeze-dried blueberries (n=13). Body mass index,
blood pressure, hemoglobin A1c, serum lipid profiles, glucose, and high-sensitivity C-reactive
protein (hsCRP), and plasma thiobarbituric acid reactive substances (TBARS) were assessed at
baseline and the end of the study. A food frequency questionnaire was administered to assess
dietary intake. A two-sample t-test was performed on nonsmokers (n=14) and smokers (n=31)
at baseline to assess the effects of smoking on CVD risk factors in postmenopausal women and
are reported as means ± SD. Following treatment, data were analyzed as percent change by
group using a randomized, one factor analysis of variance (ANOVA) followed up with a
protected least significant differences (LSD) test. This study showed that smokers had
significantly higher serum triglycerides and lower high-density lipoprotein cholesterol than
nonsmokers; 130 ± 11 mg/dL vs. 87 ± 7 mg/dL (p=0.0010) and 58 ± 3 mg/dL vs. 66 ± 3 mg/dL
(p=0.0384), respectively. There were no significant effects of blackberry or blueberry treatment

for three months in ameliorating risk factors associated with CVD in postmenopausal smokers.
The effects of berries on CVD risk factors needs to be elucidated in a larger sample size.
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CHAPTER 1. INTRODUCTION
Greater than 1 in 3 females in the United States live with cardiovascular disease (CVD)
and it is the leading cause of mortality in women, with more than twice as many deaths than all
forms of cancer combined [1]. Modifiable risk factors for CVD include diabetes mellitus, high
serum lipids, high blood pressure, metabolic syndrome, overweight or obesity, physical
inactivity, and tobacco use [2]. While rates of CVD mortalities have been declining over the
years, the prevalence of risk factors remains high. Greater than 50% of people in the United
States who have had a heart attack were not at high risk based on their cholesterol values
below the ‘at risk’ threshold [3]. This has prompted many researchers and medical
professionals to seek alternative CVD prediction risk models.
Menopause greatly increases a woman’s chance for developing CVD, which is attributed
to lower levels of circulating estrogen and subsequent changes in lipid profile [4, 5]. Estrogen is
thought to act as an antioxidant due to its phenolic ring structure similar to that of other
antioxidant molecules [4]. Loss of estrogen leads to inflammation and reduced antioxidant
protection in cells, especially of the vasculature, due to estrogen-estrogen receptor
interactions. Following menopause, there is an unfavorable shift in lipid profile, such as an
increase in low-density lipoprotein cholesterol (LDL-C) and triglycerides, a decrease in highdensity lipoprotein cholesterol (HDL-C), and an overall increase in total cholesterol (TC) [5].
Furthermore, one in five women are cigarette smokers, which exacerbates the risk
factors for CVD [1]. Cigarette smoking is the leading cause of preventable death in the US [6]
and a direct cause of an increased risk for heart attack and coronary artery disease (CAD) [7].
This is associated with an increase in oxidative stress and inflammation, adverse changes in
serum lipid levels, decreased nitric oxide availability, and activation of platelets [7, 8]. Smokers
have been shown to have high inflammation and oxidative stress levels measured by C-reactive
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protein (CRP) and thiobarbituric acid reactive substances (TBARS), respectively [8].
Epidemiological studies have shown that diets rich in fruits, vegetables, and whole grains
significantly reduces the risk of developing cardiovascular diseases [9, 10]. This in part has been
attributed to their antioxidant content, specifically phenolic compounds. Blackberries and
blueberries contain significant amounts of anthocyanins and total phenolics [11, 12], which can
serve to reduce inflammation and oxidative stress levels. Blueberries have shown to improve
cardiovascular health in a rat model of hypercholesterolemia [13] and antioxidant levels in
humans [14], while blackberries have shown to improve serum and liver lipids in an animal
model of postmenopausal hypercholesterolemia [15]. Therefore, the goal of this study was to
evaluate the efficacy of blackberries and blueberries in reducing CVD risk factors in
postmenopausal smokers.

Hypothesis
The hypothesis of this study was that smoking significantly increases risk factors
associated with CVD, such as serum cholesterol levels and markers of inflammation and
oxidative stress; and that antioxidant-rich blackberries and blueberries would be effective in
significantly reducing these risk factors.

Objectives
To test the hypothesis, we had two objectives:
1. To assess the effects of smoking on cardiovascular disease risk factors in
postmenopausal women.
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2. To determine the efficacy of antioxidant-rich berries in ameliorating risk factors
associated with cardiovascular disease in postmenopausal smokers.
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CHAPTER 2. REVIEW OF LITERATURE
Cardiovascular Disease
Cardiovascular disease (CVD) is the leading cause of mortality in the United States. It is
prevalent in greater than 1 in 3 Americans and was responsible for 33.6% of deaths in 2007.
CVD, or heart disease, is a broad term describing a class of diseases involving the heart or
blood vessels, including hypertension, stroke, heart attack, and coronary heart disease (CHD).
Although CVD deaths have been declining for years, the prevalence of CVD and its risk factors
remains high [6]. It is a major financial burden, with estimated direct and indirect costs
exceeding $503 billion dollars in 2010 [1]. The focus of preventing cardiovascular disease has
been on alleviating factors that have been associated with an increased risk. One of the largest
epidemiological studies to date, The Framingham Heart Study, began in 1948 with the objective
of identifying risk factors that contribute to CVD. The ongoing study with more than three
generations of participants has not only led to association of risk factors for CVD, but also how
these factors increase the risk for CVD. The study identified major risk factors as high blood
pressure, high blood cholesterol, smoking, obesity, diabetes, menopause, and physical activity,
and the prevalence of these risk factors can be seen in all racial and ethnic groups [16, 17].
Recent data from 2007 showed that an estimated 34% of US adults had hypertension,
23% of men and 18% of women were cigarette smokers, 15% had total serum cholesterol levels
≥240 mg/dL, 8% had diagnosed diabetes mellitus, and 37% had prediabetes [6]. These risk
factors are of interest because they lead to an increase in inflammation and promote the
formation of atherosclerosis, a condition in which fat, cholesterol, and other substances
accumulate on the innermost layer of the artery [18]. This plaque formation can harden
overtime, impede blood flow, and cause coronary heart disease. Therefore, inflammation and

4

subsequent atherosclerosis formation play a pivotal role in the etiology of cardiovascular
diseases through these various risk factors.
Rosamond and others [16] have identified optimal, elevated, or major risk factor levels
associated with CVD. Optimal risk factors at age 50 for both men and women include a blood
pressure at or below 120/80 mmHg, total cholesterol below 180 mg/dL, and no presence of
diabetes or smoking, shown in Table 1. An elevated risk is defined as stage I hypertension –
blood pressure of 140-159/90-99 mmHg, or cholesterol levels of 200 to 239 mg/dL. Major risk
factors include stage II hypertension – blood pressure ≥160/≥100 mmHg, cholesterol above 240
mg/dL, current smoking, and diabetes. Men and women with optimal risk factors have greater
than 10 years median life expectancy as compared with those with 2 or more major risk
factors.
Table 1. Optimal CVD Risk Factors at Age 50
for Men and Women
Blood Pressure
<120/80
Total cholesterol
<180 mg/dL
Fasting blood glucose
<126 mg/dL
Nonsmoker
At age 40, the risk of developing coronary heart disease (CHD) is one in two for men
and one in three for women. Comparable rates of first cardiovascular events occur 10 years
later in life in women when associated with risk in men. This disparity diminishes with age and
rates become higher in women after menopause [17, 19-21]. Menopause has been studied
extensively in an attempt to elucidate the cause of increased risk for coronary heart disease
compared to premenopausal age-matched women. Studies have shown an association between
menopause and an unfavorable change in serum lipids, increase in inflammation and oxidative
stress, and decreased antioxidant protection of cells [5, 22, 23].
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Postmenopausal Cardiovascular Disease
The cardioprotective effects of estrogen can be seen by the lower rates of CVD in
premenopausal women compared to age-matched male counterparts [1, 24, 25]. A large
percentage of women entering menopause exert no signs of CVD, however, many develop the
disease following the transition into postmenopausal status [26]. This increase is attributed to
the loss of circulating estrogen, the predominant sex steroid hormone in women.
Endogenous circulating estrogen in the form of estradiol, or E2, plays crucial direct and
indirect physiological effects within the vasculature shown in Table 2. Direct effects include an
increase in nitric oxide (NO) synthesis, vasodilation, and endothelial cell growth, and a decrease
in vascular injury and smooth muscle cell proliferation [5, 27, 28]. Indirect effects involve a
decrease in atherosclerosis and vascular injury, an increase in endothelial cell growth,
maintenance of healthy serum lipoprotein levels, and decreased lipid oxidation [5, 22, 23].
Therefore, E2 is involved in maintenance of the blood vessel lining, fluid and hormone balance,
and proper lipoprotein levels.
The physiological roles of estrogen are possible through estrogen-receptor interactions.
Estrogen receptor alpha (ERα) [27] and estrogen receptor beta (ERβ) [28] control the
mechanisms of E2, however, ERα predominates in vascular cells of men and women, providing a
good model for comparing the effects of hormonal differences linked to cardiovascular diseases
[29]. Men lacking functional estrogen receptors have weakened vascular functioning and early
calcification of the coronary artery [30]. Women with atherosclerotic coronary arteries have
fewer estrogen receptors than those with normal coronary arteries [31]. The direct and
indirect effects of estrogen are outlined below.
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Table 2. Direct and Indirect Effects of Estrogen
Direct
Indirect
Increase nitric oxide synthesis
Decrease LDL-C
Increase in vasodilation
Increase triglycerides
Increase endothelial cell growth
Increase HDL-C
Decrease smooth muscle cell proliferation Decrease lipid oxidation
Direct Effects of Estrogen
Estrogen is a critical cofactor in the nitric oxide synthase (NOS) pathway that directly
induces vasodilation and initiates NOS genes [5, 32]. Fluctuations in blood pressure correlate
with circulating estrogen levels in women during menstrual cycles and pregnancy [33], hence,
estrogen is important for maintaining optimal blood pressure levels. Differences in blood
pressure in age-matched men and women confirm that premenopausal women have lower
blood pressure levels than age-matched counterparts. ERβ, although in proportionally smaller
amounts in vascular tissue, plays a key role in blood vessels and functioning ERβ is also needed
for normal dilation and blood pressure in men and women. Short-term estrogen administration
in men has little effect on blood pressure, but long-term estrogen therapy improves
vasodilation [34].
Nitric oxide synthase can be induced (iNOS) or is constitutively expressed in the
endothelial (eNOS) cells of blood vessels [35]. The eNOS isoform functions to dilate blood
vessels, prevent leukocyte adhesion, and inhibit proliferation of smooth muscle cells [32]. The
expression of eNOS can be increased or decreased by stress and other environmental agents.
A complex of an estrogen receptor and eNOS is needed for a functional signal and diminished
availability of estrogen causes a decrease in eNOS and an increase in blood pressure and
leukocyte adhesion. Factors such as smoking, diabetes, and hypertension lead to excess
production of a superoxide (O2-) reactive oxygen species (ROS) that interacts with NO to form
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peroxynitrite, a highly reactive molecule. This biochemical cycle is continuous because
peroxynitrite causes eNOS to become reactive and begins generating superoxide ions itself
[36]. The production of superoxide ROS can increase levels of oxidative stress if antioxidant
protective mechanisms are not sufficient enough to scavenge the highly reactive molecules.
Estrogen exhibits antioxidant effects that may indirectly resist oxidative stress. In addition,
estrogen indirectly effects the expression of apolipoprotein gene expression and levels of serum
lipoproteins.

Indirect Effects of Estrogen
The abnormal changes in serum lipoprotein and triglyceride levels in postmenopausal
women are due to apolipoprotein gene expression in the liver and altered lipoprotein
metabolism. Apolipoproteins are proteins that bind to cholesterol to form lipoproteins.
Apolipoprotein A (Apo A) is the major protein in HDL-C and apolipoprotein B (Apo B) is the
predominant protein in LDL-C. ApoA and ApoB play a role in the development of
atherosclerosis. Lipoprotein a (Lp(a)), discovered in the 1960’s, is linked to transport of LDL-C
and initiation of the blood clotting process. Lp(a) is comprised of LDL-C and the Apo A protein
and selectively found in certain individual’s serum, but not all. There is a positive correlation
between serum Lp(a) concentration and risk for heart attack, leading to the idea that Lp(a) may
be an independent risk factor for atherosclerosis [37].
Studies have shown that postmenopausal women experience undesirable changes in
serum lipids, increasing the risk of developing CVD [22, 23]. This includes a rise in low-density
lipoprotein cholesterol and triglyceride levels, and a decrease in high-density lipoprotein
cholesterol levels [5, 38]. Significant changes occur during the menopausal period and time since
menopause correlates with increased atherogenesis and other vasculature changes [39].
8

Atherogenesis promotes inflammation because of the cascade of factors released by plaque and
foam cell accumulation on the arterial wall. Within three years following natural menopause,
there is a significant increase in total cholesterol and LDL-C [40], compared with an increase
after six weeks following ovariectomy [41]. Approximately five to eight years following
menopause, there is a significant increase in intima-media thickening and formation of plaque
deposits [42], contributing to atherogenesis.
A prospective study by Matthews et al. [43] examined changes in coronary heart disease
risk factors within a year of the final menstrual period. Participants were 1,054 women from the
Study of Women’s Health Across the Nation. Women were examined annually during the early
follicular phase of the menstrual cycle to normalize for fluctuating hormones. They saw
substantial increases in total cholesterol and LDL-C within the one-year interval before and
after the final menstrual period. Therefore, researchers have suggested that ApoB, the major
protein that comprises LDL-C, and Apo A, the major protein that comprises HDL-C, also be
part of the cardiovascular screening process [20] because of the role they play in lipoprotein
levels.
Preventing changes in cholesterol levels and formation of atherosclerotic plaque should
be of importance before total cessation of menses as physiological changes may have taken
place during the period of diminishing estrogen levels and before the final menstrual period. The
menopausal transition can take up to 3 years before menses ceases and during this time,
estrogen levels are slowly diminishing. The diminished circulating estrogen affects the entire
vascular system and decreases the antioxidant protection in cells.

Estrogen as an Antioxidant
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It is proposed that estrogen acts as an antioxidant because of its phenolic hydroxyl
group [4]. Short- and long-term administration of 17β-estradiol in postmenopausal women has
shown to decrease oxidation of LDL-C [5, 44]. In vivo mice studies demonstrate that
ovariectomy causes an increase in serum and liver lipid peroxide levels within one month and a
significant difference is seen between ovariectomized and sham control mice within three
months [45]. Serum or liver lipid peroxide levels are sensitive markers of LDL-C oxidation that
induces oxidative stress. One year later, a follow-up clinical trial [46] compared 18
premenopausal women with 10 naturally postmenopausal women and saw a significant
difference (p<0.05) in serum lipid peroxide levels at the beginning of the study. After 7 of the
premenopausal women underwent ovariectomy, serum lipid peroxide levels were examined 15,
30, and 60 days after the operation to assess changes. Sixty days after surgery, serum from five
subjects confirmed an increase in levels (p<0.05). The increased serum lipid peroxide levels
observed in postmenopausal and ovariectomized women compared to premenopausal women
demonstrates estrogen’s role as an antioxidant and its preventative effect against oxidative
damage. Further complicating the consequences of menopause, smoking can greatly influence
the timing and onset of menopause, severity of symptoms, and contributes to the development
of CVD by many of the same mechanisms.

Smoking and Cardiovascular Disease
Roughly 21.1 million, or 1 in 5, American women are cigarette smokers and the risk for
ischemic stroke in smokers is double that for nonsmokers [47]. Smoking is the leading cause of
preventable disease and deaths in the United States and a major cause of cardiovascular disease
among women [6]. It is the single most important factor in the development and progression of
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atherosclerosis [7, 48]. Smoking leads to an increase in inflammation and oxidative stress, a
reduction in nitric oxide (NO) availability, and activation of blood clotting platelets [8]. There is
an unfavorable shift in blood lipids of long-term smokers and a continuous activated immune
response that leads to an increase in chronic inflammatory markers, such as C-reactive protein.
Postmenopausal smokers are at serious risk for developing heart disease and its related
comorbidities.

Vasomotor Dysfunction
Smoking is associated with a decrease in vasomotor dysfunction through damaged nitric
oxide molecules. Cigarette smoke causes a 20 to 25% increase in blood leukocyte count [49] as
well as elevated L-selectin expression, an adhesion molecule that brings white blood cells
(WBC) to the endothelium of inflamed tissue [50]. Slight systemic changes are seen in levels of
inflammatory intermediates in the lungs and circulation of healthy smokers. NO controls
inflammation through leukocytes, platelets, and thrombocytes [51]. There is a strong
correlation between cigarette smoking and acute phase proteins, such as fibrinogen and Creactive protein [52-54], a marker of chronic inflammation. Inflammation has been shown to
produce reactive oxygen species, which promotes oxidative stress [55].
The tar and gas phases of cigarette smoke contain more than 1017 and 1015 free radicals,
respectively. The free radicals contained in the tar phase are long lasting compared to the
radicals contained in the gas phase. Cigarette smokers are exposed to 8% tar and 92% gas
components [56] while actively engaging in smoking. Second-hand smoke contains 85% of the
side stream smoke and 15% of the mainstream smoke from smokers [57], however, the
second-hand smoke contains higher concentrations of toxic gas components than mainstream
smoke because of the lack of filter [58]. To further damage healthy cells, smoking decreases the
11

bioavailability of NO through generation of ROS and reduction of the antioxidant capacity of
the cell [48]. The free radicals from cigarette smoke and activated endogenous free radicals,
such as uncoupled nitric oxide synthase (NOS), xanthine oxidase, and nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase, trigger an increase in lipid peroxidation [7]. The
imbalance between oxidative stress and the internal antioxidant protection increases oxidation
of lipids, proteins, and DNA and creates an impaired protection mechanism in cells [59]. This
has negative implications on serum lipoproteins as seen in the differences in lipid profiles in
smokers when compared to age-matched nonsmokers.

Changes in Lipid Profile
Alterations in serum cholesterol levels may be the primary reason for the development
of atherosclerosis in smokers. Smokers have increased levels of total serum cholesterol,
triglycerides, and LDL-C, and decreased high-density lipoprotein cholesterol (HDL-C) [60]. This
creates an unfavorable lipid profile in which the total cholesterol:HDL-C ratio drops, a strong
risk factor for the development of atherosclerosis. Abnormalities of serum lipids could be
caused from a number of notable differences among smokers compared to sex- and agematched non-smokers. For instance, smokers have significantly lower serum antioxidant vitamin
C, beta-carotene, and beta-cryptoxanthin levels, even after accounting for dietary intake [61].
These are antioxidant vitamins that could, at effective levels, protect against the damage of lipid
oxidation. Cigarette smoke also oxidizes glutathione (GSH), one of the predominant
endogenous antioxidants that functions to rid the body of harmful peroxides and maintains
vitamins C and E in their reduced forms so they are accessible to cells [62]. Prevention and
treatment of CVD should focus on maintaining normal levels of biomarkers of inflammation and
oxidative stress or alleviating the cause of high levels of such biomarkers.
12

The Importance of Measuring Inflammation and Oxidative Stress
Greater than 60% of people who develop coronary events have one or less traditional
risk factors present and more than 50% have normal or slightly increased lipid values [18]. This
has prompted many researchers to ask that high-sensitivity C-reactive protein (hsCRP) be used
in predicting risk of cardiovascular disease events. Inflammation is an important element in the
development and progression of atherosclerosis. The Physicians’ Health Study [63] and the
Framingham Heart Offspring Study [64] showed clinical significance in using hsCRP as
independent predictors for CVD risk. The American Heart Association and Centers for
Disease Control published guidelines on assessing risk according to levels of hsCRP; below 1
mg/L correlates with low risk, medium risk is levels between 1 and 3 mg/L, and high risk is
levels over 3 mg/L (Clinical Chemistry 55:2 2009). Individuals may be more accurately classified
as ‘at risk’ if hsCRP was added to clinical risk prediction criteria for CVD. Inflammation and
oxidative stress are closely linked and one can further increase the other.
Very simply, oxidative stress is the imbalance between free radical production and the
body’s antioxidant defenses and has been implicated in a number of conditions, such as
cardiovascular disease, cancer, diabetes, rheumatoid arthritis, and aging [65, 66]. Animal models
support the hypothesis that oxidative stress plays a causal role in vascular diseases such as
atherosclerosis. Large human investigations support this hypothesis because oxidative stress is
implicated in many of the risk factors for CVD [67]. Oxidative stress can be quantified by
measuring levels of lipid peroxidation. There are several methods for measuring lipid
peroxidation, however, thiobarbituric acid reactive substances (TBARS) assay remains the most
widely used assay [68]. TBARS is specific for malondialdehyde (MDA), which is a naturally
occurring produce of lipid peroxidation in cells and tissues [68, 69]. Lipid peroxides, derived
from polyunsaturated fatty acids, can easily degrade to smaller compounds, i.e. MDA. The assay
13

procedure consists of forming an adduct of MDA, in this case contained in plasma, and
thiobarbituric acid (TBA) in conditions of high temperature and acid, i.e. 100°C and acetic acid.
Normal TBARS concentration in human plasma is 1.86 – 3.94 µM MDA [68]. Orhan and
others [70] found that TBARS were significantly elevated in smokers when compared to
nonsmoker controls (p<0.01). Ochs-Balcom [71] and colleagues measured TBARS levels in
1,197 men and 1,149 women ages 35-79 with no significant differences in body mass index or
pack-years smoking and found that men had a higher TBARS value than women (1.44 vs. 1.33
nmol/mL, p<0.01). They concluded that the lower TBARS values in women could be due to the
antioxidant activity of estrogen, however, Ide and others [72] concluded that plasma estrogen
did not explain differences in TBARS levels. The debate remains about estrogen’s ability as an
antioxidant, but women have shown to have higher levels of antioxidant vitamins such as
vitamin E and β-cryptoxanthin [71]. The higher levels of antioxidant vitamins in healthy
premenopausal women compared to age-matched men could be due to the fact estrogen
quenches free radicals and other antioxidant vitamins remain in circulation until otherwise
needed.
Another method of measuring lipid peroxidation is isoprostane levels by gas
chromatography-mass spectrometry, a highly reliable and specific method [73]. Specifically, F2isoprostanes, measurable in plasma, serum, and urine, are prostaglandin-like compounds that
are the products of lipid peroxidation of arachidonic acid [74]. Isoprostanes are greatly
influenced by the amount of cigarettes smoked, so they are a reliable marker for an accurate
quantification of inflammation. The drawbacks to measuring isoprostanes for quantifying
oxidative stress levels are cost of buying the isoprostane standard and prolonged time validating
a method for GC-MS specifically for F2-isoprostanes. Pilz and others [75] observed the
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isoprostane levels in 47 adult smokers. Baseline levels of plasma, serum, and urinary 8-epi-PGF2α
were significantly increased in smokers compared to nonsmokers. A reduction in levels was
seen only a few days following cessation and reached normal levels after 4 weeks [76]. These
results indicate that individuals may benefit from smoking cessation and levels of oxidative
stress may return to normal [77].
Smoking and menopause are risk factors for CVD because they increase levels of
inflammation and oxidative stress and over time this can cause vasomotor dysfunction, changes
in lipid profile, an exhausted immune system, and decreased protection in cells throughout the
body.
It is of concern to health professionals to prevent the onset of cardiovascular disease by
maintaining optimal levels of CVD risk factors. Because it is the number one cause of mortality
in the United States, it remains a burden to a large proportion of US adults and is a focus for
many scientific professionals as well.

Current Prevention and Treatment of CVD
Menopause is an unavoidable process for women. Those who have experienced
menopause report the occurrence of hot flashes, sleep disturbance, emotional and sexual
imbalance, nervousness, and vasomotor symptoms [78]. Smoking has been reported to
negatively affect the timing of menopause and its related symptoms [79]. The Women’s Health
Initiative showed that hormone replacement therapy (HRT) increases the risk for heart disease,
stroke, and cancer of the breast and endometrium [80], and is no longer recommended.
Current recommendations for preventing heart disease in women include smoking cessation,
maintaining a healthy body weight, exercise, controlling medical conditions, and eating well.
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However, treatment is generally not recommended until CVD risk factor levels have already
transitioned into the ‘at risk’ or ‘high risk’ categories, or following a cardiovascular event. The
traditional method of treating CVD includes maintaining a healthy diet, exercising regularly, and
pharmaceutical applications.

Pharmaceutical Therapy for CVD
There are several pharmaceuticals that have been developed to target risk factors of
CVD. Statins, the most commonly prescribed class of drugs, target high cholesterol levels
through an enzyme that inhibits cholesterol synthesis in the liver. Although rare, cases have
been reported of liver failure and other common side effects include nausea, vomiting, diarrhea,
and constipation [81]. Nitrates are potent vasodilators that target high blood pressure and use
of nitrates has been linked to sudden drops in blood pressure, fainting, dizziness, and heart
palpitations. Other medications – ACE inhibitors, calcium channel blockers, diuretics, and blood
thinners – have their own lists of side effects [82]. Therefore, compliance is low and patients do
not want to cope with the side effects of drug treatment or the financial burden associated with
the cost of prescription. Consequently, many women are looking for a natural, safe alternative
to drug therapies. Risk factors for CVD, such as high cholesterol, obesity, hypertension, and
diabetes, have shown to be significantly influenced by diet and lifestyle and these factors have
been increasingly popular targets of CVD treatment.

Dietary Therapy for CVD
The American Heart Association has outlined diet recommendations for reducing the
risk of cardiovascular disease [83]. These include consuming a diet rich in fruits and vegetables,
choosing whole grains over refined grains, eating high-fiber foods, consuming oily fish at least
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twice a week, limiting saturated and trans fat intake, choosing lean meats, and limiting intake of
beverages and foods with added sugars. These recommendations evolved from studies that
examined the effects of dietary patterns on CVD risk and risk factors [84, 85]. Studies have
shown that dietary consumption of fruits, vegetables, and grains significantly reduces the risk of
developing CVD, type 2 diabetes, aging-related diseases, and some cancers [10, 86, 87].
Specifically, fruits and vegetables have been implicated in a number of population-based
studies as having beneficial effects on biomarkers associated with risks of cardiovascular disease,
primarily LDL-C. These positive results have been attributed, in part, to the non-macronutrient
composition, such as vitamins, minerals, fiber, and phytochemicals, such as phenolic compounds.
Blackberries and blueberries are predominantly carbohydrates, a good source of fiber,
extremely low in sodium, contain very little fat in the form of healthy unsaturated fatty acids,
and a large number of phenolic compounds [88], which are known to act as potent free-radical
scavenging antioxidants.

Antioxidants
Antioxidant-rich foods have become popular in recent years due to the growing
concern over the negative consequences of oxidative stress and dietary antioxidants counteract
the formation of free radicals [89]. Free radicals are generated by factors such as the body’s
metabolism, UV rays from sunlight, air pollution, cigarette smoke, pesticides, and drugs. Free
radicals are molecules that contain an unpaired electron in their outer orbital shell [65]. They
are unstable, extremely reactive, and have a strong tendency to stabilize themselves by
“stealing” electrons from other molecules, such as proteins, lipids, and nucleic acids. Thus, free
radicals cause cellular injury or death to otherwise healthy cells in the body. Antioxidant
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availability in vivo would prevent free radicals from starting the cascade of oxidative stress
formation.
The most common free radicals are oxygen-derived, including superoxide, hydroxyl,
peroxyl, alkoxyl, and hydroperoxyl, belonging to a group classified as reactive oxygen species
(ROS) [66]. These ROS produced by endothelial cells, smooth muscle cells, and macrophages
oxidize LDL-C [67]. Oxidized LDL-C molecules form foam cells, a major component of
atherosclerotic plaque that accumulates on the vascular wall. In addition, oxidized LDL-C
stimulates expression of adhesion molecules and chemotactic factors that help monocytes and
other leukocytes attach to the arterial wall [90], further promoting ROS production. Foam cells
and leukocytes cause fatty streaks, smooth muscle proliferation, and lead to an unstable fibrous
plaque susceptible to rupture [67]. Without sufficient levels of antioxidants, the generation of
ROS and increase in oxidative stress levels could hinder cardiovascular health.
Current antioxidants used in the prevention of cardiovascular disease include vitamins E,
C, and β-carotene [91]. Multivitamins are commonly recommended by physicians, however,
those containing α-tocopherol and β-carotene and taken on a regular basis may cause adverse
effects because these vitamins are fat-soluble and stored readily by the body. Furthermore, they
show no effect in decreasing the risk for cardiovascular mortality and may cause negative
consequences on lipid concentrations [91, 92].
The Heart Protection Study was a randomized, placebo-controlled study [91] in 20,536
high-risk individuals investigating statin medication and vitamin use. They found no significant
differences in cardiovascular mortality with vitamin E, vitamin C, and β-carotene
supplementation for five years. There was increased plasma concentrations of these nutrients
and dosage level appeared to have no adverse effects at the end of the study period. The lack of
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significant positive findings as a consensus for antioxidant supplementation in CVD suggests that
antioxidants may be more beneficial when consumed from whole foods and that separate
classes and/or subclasses of antioxidants, such as phenolic compounds, may exhibit more potent
in vivo effects than antioxidant vitamins C, E, and β-carotene.

Phenolic Compounds
Phenolic compounds have been shown to resist platelet aggregation, reduce
proinflammatory mediators, and decrease expression of adhesion molecules, making them
antithrombotic [93]. Phenolic compounds are secondary metabolites present in all plants [94],
however, flavonoids are the most abundant phenolic compounds in plant foods. Table 3 shows
flavonoid subclasses, compounds, and typical foods with high content taken from the United
States
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Table 3. Flavonoid Subclasses, Compounds, and Good Food Sources
Subclass
Compounds
Good food sources
Flavonols
Quercetin, Kaempferol, Myricetin,
Onions, broccoli, apples,
Isorhamnetin
berries, tomato, grapes, tea,
red wine
Flavones
Luteolin, Apigenin, Tangeritin
Celery, parsley
Flavanones
Hesperetin, Naringenin, Eriodictyol,
Oranges, grapefruit, lemons
Homoeriodictyol
Flavan-3-ols
Catechin, Gallocatechin, Epicatechin,
Apples, blackberries, red
Epigallocatechin, Epicatechin 3-gallate,
wine, green tea, black tea
Epigallocatechin 3-gallate, Theaflavin,
Theaflavin 3-gallate, Theaflavin 3’-gallate,
Theaflavin 3,3’ digallate, Thearubigins
Anthocyanidins
Cyanidin, Delphinidin, Malvidin,
Blackberries, blueberries,
Pelargonidin, Peonidin, Petunidin
raspberries, red wine
Proanthocyanidin Monomers and polymers of flavonoids
Apples, chocolate, red
seeded grapes
Isoflavones
Daidzein, Genistein, Glycitein
Tofu, soymilk
Adapted from the US Department of Agriculture databases for isoflavone, flavonoid,
proanthocyanidin content of selected foods [95-97]

Flavonoids improve endothelial function and inhibit platelet adherence [98-100], and
therefore, are thought to reduce the oxidation of LDL-C [101, 102]. Flavonoids have been
shown to inhibit lipid peroxidation via the phospholipid bilayer by trapping radicals at the
interface of the membrane and preventing a chain reaction of generating free radicals and
damaging other lipids [103]. Furthermore, they can chelate metal ions that could generate ROS
and inhibit lipoxygenase reactions [104]. These effects are thought to contribute to flavonoids’
role in reducing oxidative stress and inflammation, and reducing the risk of CVD.
Epidemiological studies show conflicting results between flavonoid intake and stroke or
CVD mortality. Several epidemiological studies have found a significant inverse relationship
between flavonoid intake and cardiovascular disease in women [105-107]. The Zutphen Elderly
Study [105] showed that a flavonoid intake of 30 mg/day was associated with a 50% reduction in
CHD mortality when compared to a diet with less than 19 mg/day. Knekt and colleagues [108]
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in a cohort study of 10,054 Finnish men and women concluded that higher intake of quercetin,
a specific flavonoid, was associated with a lower mortality from ischemic heart disease (p=0.02).
Some studies have disputed this relationship [109, 110]. Yochum and others [110] found no
association between flavonoid intake and stroke mortality in 34,492 postmenopausal women.
The discrepancies associating flavonoid intake with CVD rates and mortality may be due
to the varying amount of flavonoid-containing foods in certain populations, the variability of
amount of flavonoids within a food [94], and the statistical approach when analyzed. For
example, Hertog et al. [111] combined total flavonoid intake, saturated fat, and smoking in a
multivariant analysis of coronary heart disease. Knekt and others [108] analyzed only one
flavonoid compound and concluded that higher intakes of quercetin was associated with
decreased mortality from ischemic heart disease.
Anthocyanins are a class of flavonoids which have been studied exclusively and shown to
be potent antioxidants with anti-inflammatory and cell regulatory properties [112]. Blackberries
and blueberries are rich in anthocyanins and have been shown to improve the cardiovascular
system in an animal model [13, 15].

Anthocyanins
The in vivo effects of anthocyanins are thought to be largely dependent upon stability and
bioavailability. Anthocyanins are comprised of phenolic ring structures known as anthocyanidins
and their sugar moieties. In vitro studies [113] show that anthocyanins in their aglycone form are
extremely unstable at neutral conditions and relatively stable in acidic environments. The
stability is also dependent upon the attachments at R1 and R2 on the B-ring of the anthocyanidin
structure. Hydroxy and methoxy groups attached on the aglycone structure decrease the
stability, therefore, pelargonidin remains the most stable anthocyanidin. Cyanidin and peonidin
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contain hydrogen molecules at R2 and hydroxy and methoxy groups at R1, respectively and are
slightly stable. The basic structure of anthocyanidins is shown in Figure 1.

Anthocyanin-monoglucosides are stable at neutral pH because the sugars prevent
degradation. However, incubating anthocyanin-3-glucosides such as cyanidin, malvidin, and
peonidin 3-glucosides with human fecal microflora resulted in more than 90% degradation after
2 hours indicating that gut microflora are largely responsible for the degradation of
anthocyanins into phenolic acids. Bacterial biotransformation of the microflora is responsible
for cleaving the sugar to leave the aglycone anthocyanin and because the pH of the colon can
reach 8.0, this may be an unstable environment for anthocyanidins [114]. It was previously
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believed that dietary flavonoids were minimally absorbed, however, studies have been shown
that some are absorbed better than others.
The sugar moiety of anthocyanins and other flavonoids is also an important component
affecting the absorption and bioavailability in vivo. Hollman and others [114] observed
absorption of quercetin, which is a flavonol in both blackberries and blueberries, in nine
patients who had undergone ileostomy. After following a 12 day quercetin-free diet, subjects
consumed one of three supplemented diets (100 mg) over a 12 day period: 1) fried onions with
quercetin glucosides; 2) pure quercetin rutinoside; or 3) pure quercetin aglycone. They found
that absorption of quercetin aglycone was lower than quercetin glycosides (24% vs. 52%),
indicating the sugars increased absorption of quercetin when compared to the aglycone form. In
a single-blind study conducted by Kay and Holub [14], consumption of 100 g of freeze-dried
blueberry powder with a high-fat diet led to an increase in serum antioxidant levels shown by
the oxygen radical absorbance capacity (ORAC) assay. Compared to a control high-fat diet fed
one-week prior, after consuming the 100 g blueberry powder, there was an 8.5% increase in
serum ORAC after 1 hour (p=0.02) and a 15% increase after 4 hours (p=0.009). Conversely,
when six healthy women consumed 189 g of frozen blueberries containing 690 mg anthocyanins
in 315 mL water, anthocyanins were difficult to detect in urine. Approximately 0.004% of the
690 mg anthocyanin consumed was detected in urine. There were no anthocyanins detected in
any of the plasma samples at any given time point (10 minutes-24 hours). This may be because
there are over 25 different anthocyanins in blueberries [115] and such small amounts of each
that they are all degraded rather quickly in circulation or because of their poor lypophilic
properties.
Anthocyanins from blackberries have been shown to be slightly absorbed in humans.
Four healthy women consumed 720 mg anthocyanins derived from elderberries in 500 mL
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water. Cyanidin 3-glucoside, the predominant anthocyanin in blackberries, was found in urine
and plasma samples from all subjects within 4 hours following consumption [116]. Consumption
of 200 g blackberries (89.2% cyanidin 3-glucoside) concurrently with 15 g sugar, 60 g of bread,
and 10 g of butter resulted in the highest identifiable cyanidin 3-glucoside peak and its related
metabolites in urine between 2 and 4 hours following consumption. A 24-hour urine collection
revealed that excretion of the native cyanidin 3-glucoside accounted for just 0.023% of total
ingested amount and metabolites accounted for 0.16% of ingested amount [117]. Cyanidin 3glucoside and other anthocyanins may be metabolized into methylated and glucuronidated
conjugates and these need to be analyzed as metabolites in plasma and urine as well as the
native anthocyanins [116], however, many of these metabolites have not yet been identified.
This chapter has focused on the risk factors for cardiovascular disease, specifically
menopause and smoking, and how they contribute to the etiology of CVD. Additionally, how
inflammation and oxidative stress play a pivotal role in the development of cardiovascular
disease in postmenopausal smokers and how antioxidant-rich berries may alleviate these risk
factors. This was a pilot clinical trial and to our knowledge, this is the first study to examine the
effects of blackberry and blueberry treatment on CVD risk factors in postmenopausal smokers.
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CHAPTER 3. METHODS
Study Design and Criteria for Participation
This study was approved by the University of Arkansas Institutional Review Board (IRB)
(Appendix 1) and Washington Regional Medical Center (Fayetteville, AR). Guidelines for a
clinical trial were followed for the entire duration of the study. The study design is shown in
Figure 2. Healthy, postmenopausal women were recruited from the Northwest Arkansas
Region by mail, radio, flyer, brochures, and email to participate in the three-month study. They
were required to meet the following criteria: have no personal history of heart disease,
refrained from using hormone replacement therapy (HRT) within three months prior to
beginning the study, and not be on any medication that would affect the outcome of the study.
Smokers were moderate smokers defined by smoking 1-20 cigarettes/day. Nonsmokers were
recruited for a control group and smokers were recruited and randomly assigned to one of
three groups: smoker control, smoker + blackberries, and smoker + blueberries. Participants
signed an informed consent (Appendix 2) and completed a full medical history questionnaire
(Appendix 3) including personal history of skeletal health, cardiovascular function, hypertension,
diabetes, gastrointestinal/digestive problems, liver disease, respiratory problems, thyroid
disorder, medication or drug use, and physical activity.

Blackberry and Blueberry Treatment
Women assigned to the blackberry and blueberry treatment groups were required to
consume 45 grams of freeze-dried berries per day and it was suggested replacing a snack with
the berries so that normal daily caloric intake was not altered. Freeze-dried blackberries and
blueberries were purchased from WaterShed Foods (Gridley, IL). Forty-five grams of berries
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were weighed and individually vacuum-packaged to retain nutritive value and for ease of storage
and transportation. Participants were given the sufficient amount of vacuum-packaged berries
needed until the final visit. Calendars were provided to participants in the treatment groups to
record compliance.

Analysis of Macronutrient Composition and Flavonoid Content of FreezeDried Berries
Upon arrival, freeze-dried blackberries and blueberries were sent to the Central
Analytical Laboratory (University of Arkansas Poultry Science Center; Fayetteville, AR) for
proximate analysis of fat, protein, dry matter, ash, and crude fiber. Percent carbohydrates were
calculated by subtracting percent fat and protein from 100. Flavonoid content was analyzed in
triplicates by high performance liquid chromatography (HPLC) using a previously outlined
method [118]. Blackberry flavonoid profiles were followed up and confirmed by mass
spectroscopy, as it was difficult to detect specific peaks when compared to the blackberry
standard.

Clinical Assessment
Participants reported to the study center at baseline and following the three-month
treatment period. They were required to fast 8-12 hours overnight and came in for collection
of laboratory values. Height, weight, body mass index (BMI), and blood pressure were
recorded. BMI was calculated as [weight (kg)]/[height (m)]2. Venous blood was collected by a
skilled phlebotomist in separate BD Vacutainer® (BD Diagnostics; New Franklin, NJ) collection
tubes designated for plasma, serum, and hemoglobin A1c (HbA1c) collection. Whole blood was
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centrifuged in a Beckman Coulter (Brea, CA) centrifuge at 1200 x g at 4°C for 20 minutes.
Plasma and serum supernates were aliquoted into separate tubes and stored at -80°C until
analysis. HbA1c was analyzed by LabCorp, Inc. (Fayetteville, AR).

Dietary Assessment
A 114-item food frequency questionnaire (FFQ) (Appendix 4) was administered at each
visit with measuring cups and spoons as references. Participants were read a list of items and
asked to report portion size and frequency of consumption over the previous 7 days. The FFQ
was analyzed by Nutrition Pro (Axxya Systems; Stafford, TX) software based on USDA
References. The following nutrients were of interest: kilocalories, total fat, saturated fat,
polyunsaturated fat, monounsaturated fat, dietary cholesterol, total carbohydrates, dietary fiber,
and protein.

Serum Lipid Profiles
Serum total cholesterol, HDL-cholesterol, and triglycerides were analyzed on an ACE
Alera clinical chemistry system (Alfa Wasserman, Inc.; West Caldwell, NJ) in duplicates using
commercially available kits, quality controls, and calibrators (Alfa Wasserman, Inc.; West
Caldwell, NJ). LDL-cholesterol was then calculated using the Friedewald formula [119] as
follows: (LDL cholesterol) = (total cholesterol) – (HDL cholesterol) – [(triglycerides/5)],
whereas all values are given in mg/dL.

Inflammation and Oxidative Stress Markers
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Inflammation was quantified by high-sensitivity C-reactive protein (hsCRP) using a latex
particle enhanced immunoturbidimetric assay measured on an ACE Alera clinical chemistry
system (Alfa Wasserman, Inc.; West Caldwell, NJ) using commercially available reagents (Alfa
Wasserman, Inc.; West Caldwell, NJ). A four-point calibration curve was developed using
known concentrations of human C-reactive protein and used to determine sample
concentration in serum based on absorbance at 570 nm. The kit was sensitive for human hsCRP
between 0.1 – 160 mg/L.
Oxidative stress levels were determined by thiobarbituric acid reactive substances
(TBARS) assay kit (Cayman Chemical; Ann Arbor, Michigan). A volume of 100 µL of plasma was
used for the assay. Sodium dodecyl sulfate was added to lyse cellular membranes.
Thiobarbituric acid dissolved in a mixture of full-strength glacial acetic acid and sodium
hydroxide was added and samples were boiled at 100°C for one hour, cooled on ice, and
centrifuged 1600 x g at 4°C for 10 minutes. The supernates were taken for analysis of
concentration of plasma LDL-C peroxide products, predominantly malondialdehyde (MDA),
and read at an absorbance of 540 nm on a Synergy HT (BioTek; Winooski, VT) microplate
reader. Sample concentrations of lipid peroxidation were determined as MDA equivalents by
interpolation from the standard curve.
Statistical Methods
Baseline analysis was performed in JMP (Version 9, SAS® Institute Inc.; Cary, NC)
between controls and treatment groups to determine if groups were significantly different in
regard to age, years postmenopausal, and BMI using one-way analysis of variance (ANOVA).
Additionally, one-way ANOVA was performed on smoker control and treatment groups to
ensure smoker groups were not significantly different from one another. If ANOVA indicated
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significance (α=0.05), differences in means were determined using a protected least significant
difference procedure (LSD). A baseline two-sample t-test of nonsmokers and smokers was
analyzed to assess the effects of smoking on risk factors for cardiovascular disease. Risk factors
of interest were BMI, blood pressure, HbA1c, glucose, serum total cholesterol, LDL-C,
triglycerides, and HDL-C, hsCRP, and TBARS. Baseline results are reported as means ±
standard deviation.
Percent change of all variables after the treatment period was performed using SAS®
(Version 9.2, SAS Institute Inc.; Cary, NC). Randomized, one factor analysis of variance
(ANOVA) was performed and if indicated significance (α=0.05), was followed up by a protected
LSD procedure. Percent change results are reported as means ± standard error of the mean.
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CHAPTER 4. RESULTS
Macronutrient Composition of Freeze-Dried Berries
The proximate analysis showed that blackberries contained 6.3% fat, 87.3%
carbohydrates of which 27.7% was crude fiber, and 6.4% protein. Blueberries contained 2.3%
fat, 94.2% carbohydrates, 12.5% crude fiber, and 3.6% protein (Table 4). This provided a
calculated 195 kcal, 3 g fat, 39 g carbohydrates, 12 g fiber, and 3 g protein per day for
participants consuming blackberries and 185 kcal, 1 g fat, 42 g carbohydrates, 6 g fiber, and 2 g
protein per day for participants consuming blueberries.

Flavonoid Content of Freeze-Dried Berries
The HPLC analysis of the freeze-dried blackberries and blueberries is shown in Tables 5
and 6, respectively. Blackberries contained 631.3 ± 8.7 mg anthocyanins, 74.4 ± 0.5 mg
flavonols, and 248.8 ± 1.6 ellagitannins per 100 g blackberries, yielding a total flavonoid content
of approximately 955 mg/100 g. Cyanidin 3-glucoside comprised more than 50% of the
flavonoid composition in the freeze-dried blackberries. Blueberries contained 1449.2 ± 119.7
mg anthocyanins, 79.8 ± 6.8 mg flavonols, and 162.1 ± 4.2 mg chlorogenic acid per 100 g with
an approximate 1691 mg total flavonoids/100 g. Freeze-dried blueberries contained 29 flavonoid
compounds, approximately 85% as anthocyanins. The approximate intake of anthocyanins per
day attributed to the freeze-dried blackberries and blueberries was 276 mg and 652 mg,
respectively, and the total flavonoid intake was 430 mg and 761 mg.

Participant Characteristics
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Forty-five participants completed the study: 14 nonsmoker controls, 12 smoker
controls, 6 smoker + blackberry treatment participants, and 13 smoker + blueberry treatment
participants. A total of 65 participants were recruited for the baseline visit. Twelve did not
return for the final visit, one was excluded for being 14 years postmenopausal, one due to
complications with the baseline blood draw, one after admitted being on hormone replacement
therapy, and five based on high glucose and HbA1c values.
The average age of study participants was 55.8 ± 3.9 years old and they were 6.9 ± 3.0
years postmenopausal. Baseline values for smokers were analyzed to ensure that CVD risk
factors were not significantly different among smoker control and smoker treatment groups
(data not shown). No significant differences were observed between smoker control and
smoker treatment groups at baseline.

Effects of Smoking on CVD Risk Factors in Postmenopausal Women
Nonsmokers and smokers did not differ in regard to BMI, blood pressure, total
cholesterol, LDL-C, glucose, hsCRP, or TBARS at the beginning of the study. Nonsmokers had
significantly higher HbA1c values than smokers (5.8% ± 0.1 vs. 5.6% ± 0.1; p=0.0468) (Table 7).
Figure 3 shows the effect of smoking on serum lipid profiles. Smokers had significantly higher
triglycerides (130 ± 11 mg/dL vs. 87 ± 7 mg/dL; p=0.0010) and lower HDL-C (58 ± 3 mg/dL vs.
66 ± 3 mg/dL; p=0.0384) values than nonsmokers. Smokers had higher levels of inflammation
and oxidative stress shown by hsCRP and TBARS than nonsmokers, albeit, not significant
(Figure 4). The daily dietary intake of nonsmokers and smokers is shown in Table 8. Smokers
had significantly lower dietary fiber intake than nonsmokers (21 ± 2 g/day vs. 28 ± 2 g/day;
p=0.0166).
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Effects of Antioxidant-Rich Berries on CVD Risk Factors in Postmenopausal
Smokers
Following three months of daily treatment with 45 grams of freeze-dried blackberries or
blueberries, there were no significant changes in CVD risk factors, excluding diastolic blood
pressure (Table 9). There was a 16.08 ± 5.18% (p=0.0035) increase in diastolic blood pressure
observed following blackberry treatment.
Figures 5 illustrates the effects of berries on total cholesterol, LDL-C, triglycerides, and
HDL-C. There were no significant changes in serum lipids in either blackberry or blueberry
treatment groups. There was an increase in total cholesterol, LDL-C, and triglycerides in both
treatment groups, although insignificant. There was a slight insignificant increase in HDL-C in
the blackberry treatment group and a small decrease in HDL-C in the blueberry treatment
group. Figure 6 shows changes in inflammation and oxidative stress shown by hsCRP and
TBARS following blackberry or blueberry treatment. There were no changes in the
inflammation or oxidative stress markers, however, it is notable that the smoker control group
increased inflammation and oxidative stress by 31.12 ± 20.33% and 20.17 ± 10.82%,
respectively. These increases are not significant when compared to treatment or nonsmoker
control groups.
Table 10 shows the dietary intake of control and treatment groups at the end of the
study. Following three-months consumption of blackberries or blueberries, there were no
significant changes in dietary intake. It is notable, however, that blackberries and blueberries
caused an increase in fiber, 49.30 ± 37.79% and 80.96 ± 25.67%, respectively, compared with an
18.87 ± 26.72% increase in fiber consumption in smoker controls, however, these results are
not significant.
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CHAPTER 5. DISCUSSION AND CONCLUSIONS
The aim of this study was to investigate the effects of smoking on CVD risk factors in
postmenopausal women and evaluate the effect of antioxidant-rich berries in ameliorating those
risk factors.
Menopause has been shown to significantly increase the risk of cardiovascular disease
[120]. There is a twofold increase in CVD rates in postmenopausal women compared to age
matched premenopausal women [121]. The current study population had high levels of total
cholesterol, LDL-C, and hsCRP (Figures 3 and 4) when compared to optimal values
recommended for women [122]. Higher levels of serum total cholesterol, triglycerides, LDL-C
[123, 124] and CRP [21, 125] have been observed in postmenopausal women. This creates an
unfavorable atherogenic lipid profile putting persons at risk for heart attack and stroke, thus
could be the cause of increased rates of coronary heart disease in postmenopausal women.
Derby and colleagues [126] showed that menopausal women in the highest estradiol quartile
had the lowest levels of total cholesterol, LDL-C, and triglycerides and the highest level of
HDL-C. Studies on the effects of estrogen hormone-receptor interactions, the continuous
decrease in circulating estradiol during the shift to postmenopausal status affects lipoprotein
levels and these changes have been associated with lipoprotein metabolism [41, 127].
Additionally, we observed that smoking negatively influenced CVD risk factors in
postmenopausal women. Smokers had significantly higher triglycerides and lower HDL-C than
nonsmokers (Figure 3). These findings agree with previous studies [7, 121]. In a study of 25,689
healthy Japanese men 40-59 years old, heavy smokers had significantly lower total cholesterol,
HDL-C, and LDL-C, and higher triglycerides and atherogenic index than nonsmokers and light
smokers [128]. The increase in total cholesterol, LDL-C, and triglycerides, and decrease in
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HDL-C in smokers could be due to lower serum antioxidant levels observed in smokers [61],
although the study did not examine diet or physical activity and this may have shown significant
differences in dietary intake of fiber, vitamin A, vitamin C, or other nutrients in smokers that
may affect blood lipid levels.
The smokers in this study had higher levels of inflammation and oxidative stress than
nonsmokers (Figure 4), although insignificant. Several studies have shown a positive association
between cigarette smoking and CRP, a marker of chronic inflammation [129, 130]. Tracy and
colleagues [131] found a strong association between CRP levels and pack-years among smokers
among 400 men and women free of clinical CVD. These findings are not in agreement with the
current study findings and this could be due to the differences in sample sizes or participant
characteristics. Their population had an average age of 77 and included both men and women.
Inflammation is a cascade of events that promotes oxidative stress and reactive oxygen
species in turn will influence inflammation. It has been proposed that smoking increases
oxidative stress levels, i.e. thiobarbituric acid reactive substances (TBARS), through the deposit
of heavy metals from cigarette smoking, such as cadmium, on the arterial wall [132, 133]. The
level of cadmium in the aorta of smokers increases proportionally to the pack-years of
cigarettes smoked [133]. Other studies involving larger populations have observed significantly
higher TBARS and other lipid peroxidation values in smokers compared to nonsmokers [7,
134].
Prevention and treatment options for CVD are widely available, however, most are not
preferred or recommended due to side effects, safety, and cost [122]. Risk factors for CVD
have shown to be significantly altered by dietary habits and therefore could be a natural
alternative to drug therapy. A 6-month intervention trial [135] involving 12 healthy,
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hypercholesterolemic postmenopausal women consuming high-fat diets and 13 postmenopausal
women controls consuming low-fat diets was conducted to examine the effects of a low-fat
monounsaturated-rich diet via consumption of oleic acid-rich peanuts. Women consuming the
peanuts for 6 months experienced a significant decrease in serum cholesterol and LDL-C. This
could be attributed to the decreased intake of total fat, increase in healthy monounsaturated
fat, or increase in dietary fiber. The study population differed from ours in that the
postmenopausal women were already at elevated risk based on total fat intake and serum
cholesterol levels prior to intervention and the study period lasted 6 months, while ours was a
3-month duration.
Fiber is undoubtedly an important component of a healthy diet, however, in the
following 3-month study did not show any effects on CRP levels, an independent risk factor for
CVD. King and others [136] supplemented 7 or 14 g psyllium fiber for 3 months in 158
overweight volunteers 40-65 years old with no personal history of heart disease. At the end of
the study, there was no change in CRP, fibrinogen, or white blood cell counts in either dosage
group. This may show that fiber itself is not effective in reducing inflammation and CVD risk,
but that diets naturally high in fiber would contain additional bioactive compounds that would
alleviate risk factors. Our study supplemented 12.5 and 6.0 grams of fiber for women
consuming blackberries or blueberries, respectively, which is very similar to the fiber
supplemented in this study. Furthermore, the study population recruited was overweight
classified by BMI >25 kg/m2, which may have been an additional burden to cardiovascular health.
Our study population had an average BMI of 26.1 kg/m2, classified as overweight, and could
explain increased CVD risk factors at the beginning of the study.
The growing popularity of antioxidants in recent years is due to their health promoting
properties as a result of the ability to quench free radicals and lower oxidative stress levels.
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Berries have been shown to be anti-inflammatory [112] and inflammation is a known
component in the etiology of CVD [18, 137]. Blueberries and blackberries have been shown to
improve cardiovascular health in animal models [13, 15], however, the effects in humans are
inconsistent [138-140]. Blackberries and blueberries used in this study are rich sources of
anthocyanins and total flavonoids. A comparable study [141] involving healthy men and women,
45-61 years old, assessed CRP and blood lipids after 14 and 28 days consumption of 280 g fresh
bing sweet cherry consumption. There was no changes in CRP seen after 14 days, however,
there was a 25% reduction in CRP levels after 28 days. No changes were seen in plasma total
cholesterol, HDL-C, LDL-C, triglycerides, or particle subfractions of HDL-C or LDL-C after 14
or 28 days treatment. The amount of total phenolics in the sweet bing cherries consumed daily
was comparable to the daily phenolic intake of the blackberry treatment group in our study,
however, cherries are predominantly hydoxycinnamate and therefore, the anthocyanin
consumption is not comparable between this study and our current study. It is notable that
major anthocyanins in cherries are cyanidin 3-rutinoside and cyanidin 3-glucoside, and the major
anthocyanin in blackberries is cyanidin 3-glucoside. This may explain why we saw slightly better
improvements in hsCRP following blackberry treatment compared to blueberry treatment,
albeit not significant.
Karlsen and others showed that 300 mg/day isolated anthocyanins from bilberries
equivalent to 100 g fresh bilberries per day showed no effect on CRP, total cholesterol, HDL-C,
LDL-C, or plasma antioxidant levels after 3 week supplementation in 118 men and women ages
40-74 [142]. In a follow-up study [143] with 330 mL bilberry juice derived from steam
processing whole bilberries, they did observe a significant decrease in CRP levels after 4 weeks
of treatment. An additional study involving 255 mg/day flavonoids, predominantly cyanidin
anthocyanins, extracted from chokeberries [144] showed a significant reduction CRP levels
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after 6 weeks of treatment. Blackberries in this study are also predominantly cyanidin
anthocyanins and may modulate CRP levels similar to that of chokeberries.
Studies examining the absorption of anthocyanins in blackberries [117] and blueberries
[140, 145] have shown that anthocyanins from these two berries greatly differ in recovery in
serum and urine after ingestion, and that blackberry anthocyanins are better absorbed (0.16%)
[117] compared to blueberry anthocyanins (0.002-0.003%) [140]. While we did not examine
the recovery of anthocyanins in biological fluids or serum antioxidant status following
consumption of blackberries or blueberries, there was an amount of flavonoids that have shown
to improve CVD risk factors in previous studies. Naruszewicz [144] and colleagues observed a
significant reduction in CRP levels in postmenopausal women following 6 weeks of daily
supplementation of 255 mg/day flavonoid extract from chokeberries. Blackberries and
blueberries provided daily flavonoid amounts of 430 and 760 mg for 3 months.
Lack of positive findings from this study compared to previous literature on flavonoid
intake could be due to the specific flavonoids. Furthermore, studies have shown that the most
commonly consumed foods with highest flavonoid content are teas, apples, onions, and broccoli
[19, 105]. We did not observe any effects after three months treatment of blackberries or
blueberries on CVD risk factors in postmenopausal smokers. This may be attributed to the
small sample size of treatment groups, dose of treatment, or particular population.

Limitations and Future Research
The main limitations of this study include not having premenopausal control or a
nonsmoker treatment group. This made it difficult to compare the effects of antioxidant-rich
berries in a population that may be at lower risk for CVD. Furthermore, the potency of
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antioxidant-rich foods is dependent upon absorption and bioavailability in vivo, which were not
measured in this current study. Type of anthocyanin [113], composition of gut microflora [114],
and ingestion with other foods, such as those containing fat [14] contributes substantially to
availability of anthocyanins. Future studies examining the effects of antioxidant-rich foods in
reducing CVD risk factors in a population should investigate bioavailability, as this can vary
person-to-person and may present as confounding in human studies. Furthermore, we recruited
a total of sixty-five participants for this study and concluded the three-month study with fortyfive participants; of which we lost seven nonsmoker controls, ten smoker controls, two
smokers + blackberries, and one smoker + blueberries participants. Therefore, our group sizes
were

relatively

small

and

did

not

allow

us

to

have

strong

statistical

power.
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TABLES
Table 4. Proximate Analysis of Freeze-Dried
Blackberries & Blueberries
Blackberries
Blueberries
(%)
(%)
Carbohydrates
87.3
94.1
Crude Fiber
27.7
12.5
Protein
6.4
3.6
Fat
6.3
2.3
Data represents the mean percentage. Upon arrival, blackberries
and blueberries were analyzed in duplicates by the Central
Analytical Laboratory (University of Arkansas Poultry Science
Center; Fayetteville, AR). Percent carbohydrates was calculated
using the following: 100 – percent protein – percent fat.
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Table 5. Flavonoid Content of Freeze-Dried Blackberries
Mean
SEM
Flavonoid Compound
Identification
mg/100 g mg/100 g
Anthocyanins
Cyanidin 3-glucoside
549.1
9.7
Cyanidin 3-rutinoside
11.7
2.0
Cyanidin 3-xyloside
22.1
1.2
Cyanidin 3-malonylglucoside
17.0
0.9
Cyanidin 3-dioxalylglucoside
31.4
0.9
Total anthocyanins
631.3
8.7
Flavonols
Quercetin 3-rutinoside
29.3
0.1
Quercetin 3-galactoside
11.6
0.1
Quercetin 3-glucoside
4.3
0.1
Quercetin 3-glucuronide
4.5
0.3
Quercetin-3-O-[6"-(3-hydroxy12.0
0.2
3methylglutaroyl)]-b-galactoside
Quercetin 3-glucosylpentoside
2.0
0.1
Quercetin 3-oxalylpentoside
2.5
0.1
Quercetin 3-rhamnoside
3.2
0.1
Unidentified
3.1
0.1
Quercetin
1.9
0.1
Total flavonols
74.4
0.5
Ellagitannins
Lambertianin C isomer
99.3
2.6
Sanguiin H-6/ lambertianin A
111.8
0.3
Galloyl-bis-HHDP glucose isomer
13.0
0.1
Ellagic acid
24.4
1.6
Total ellagitannins
248.8
1.6
Total flavonoids
≈954.5 mg/100 g
Data represents mean ± SEM. Analysis was performed in triplicates by high-performance liquid
chromatography by a previously outlined method [118] and confirmed by mass spectroscopy.
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Table 6. Flavonoid Content of Freeze-Dried Blueberries
Mean
SEM
Flavonoid Compound
Identification
mg/100 g mg/100 g
Anthocyanins
Cyanidin 3-arabinoside
13.9
1.6
Cyanidin 3-galactoside
21.0
1.9
Cyanidin 3-glucoside
14.7
1.0
Delphinidin 3-acetylglucoside
36.4
1.8
Delphinidin 3-arabinoside
153.6
13.1
Delphinidin 3-galactoside
185.4
15.8
Delphinidin 3-glucoside
119.9
8.9
Malvidin 3-acetylglucoside
51.4
2.0
Malvidin 3-arabinoside
154.5
13.2
Malvidin 3-galactoside
194.8
18.7
Malvidin 3-glucoside
151.8
11.2
Peonidin 3-arabinoside
17.6
1.9
Peonidin 3-galactoside
20.6
1.5
Petunidin 3-acetylglucoside
24.6
1.0
Petunidin 3-arabinoside
85.9
8.4
Petunidin 3-galactoside
106.2
9.6
Petunidin 3-glucoside
96.8
8.4
Total anthocyanins
1449.2
119.7
Flavonols
Myricetin 3-galactoside/glucoside
13.0
0.6
Quercetin 3-acetylrhamnoside
5.5
0.5
Quercetin 3-galactoside
18.9
2.3
Quercetin 3-glucoside
5.4
0.7
Quercetin 3-rutinoside
3.6
0.3
Unidentified 1
6.0
0.3
Unidentified 2
6.0
0.5
Unidentified 3
0.5
0.0
Unidentified 4
12.3
1.5
Unidentified 5
4.0
0.3
Unidentified 6
4.4
0.1
Total flavonols
79.8
6.8
Other polyphenols
Chlorogenic acid
162.1
4.2
Total other polyphenols
162.1
4.2
Total flavonoids
≈1691.1 mg/100 g
Data represents mean mg/100g ± SEM. Analysis was performed in triplicates by highperformance liquid chromatography by a previously outlined method [118].
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Table 7. Effects of Smoking on CVD Risk Factors
Nonsmoker
Smoker
(n=14)
(n=31)
Mean
SEM
Mean
SEM
Age (years)
57.2
1.0
55.2
0.7
Years postmenopausal
8.0
0.8
7.0
0.5
Cigarettes/day (#)
--17
2
BMI (kg/m2)
25.3
1.2
26.5
0.9
Systolic BP (mmHg)
110
3
115
4
Diastolic BP (mmHg)
71
3
67
3
Glucose (mg/dL)
96
3
97
1
Hemoglobin A1c (%)*
5.8
0.1
5.6
0.1
Data analysis was run on baseline values. *p=0.0468. BMI = body
mass index; BP = blood pressure.

Table 8. Effect of Smoking on Dietary Intake
Nonsmoker
Smoker
(n=14)
(n=30)
Mean
SEM
Mean
SEM
Calories (kcal)
2042
179
1950
113
Total Fat (g)
81
9
82
5
Saturated Fat (g)
27
3
27
2
PUFA (g)
17
3
16
1
MUFA (g)
32
4
32
2
Cholesterol (mg)
303
38
323
66
Sodium (mg)
2155
170
2040
155
Potassium (mg)
3971
306
3556
184
Carbohydrates (g)
239
24
201
14
Total Fiber (g)*
28
2
21
2
Protein (g)
91
7
88
7
Data analysis was run on baseline values. *p=0.0166. PUFA =
polyunsaturated fatty acids; MUFA = monounsaturated fatty acids.
A smoker participant was removed from analysis due to outlier
values for calories, carbohydrates, and total fiber.
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Table 9. Effects of Berries on BMI, Blood Pressure,
Blood Glucose, and HbA1c
Nonsmoker
Smoker
Smoker +
Smoker +
Control
Control
Blackberries
Blueberries
(n=14)
(n=12)
(n=6)
(n=13)
Mean
SEM Mean SEM Mean SEM Mean SEM
%
%
%
%
%
%
%
%
BMI
0.60
1.85 0.16 1.07
2.89
1.44 -0.31 0.97
Systolic BP
-4.51
3.34 -4.86 3.61
6.93
5.11 -2.89 3.47
a
a
b
Diastolic BP
3.39 -2.21 3.66 16.08
5.18 -3.97a 3.52
-3.69
Glucose
-0.02
3.15 3.85 3.40
0.12
4.80 1.45 3.40
HbA1c
-0.27
5.8
-0.02 5.18
-2.3
2.70 0.40 4.98
Data represents percent change from baseline. Values in a row not connected by a
common letter are significantly different (p<0.05). A positive value indicates an increase
and a negative value indicates a decrease. BMI = body mass index; BP = blood pressure;
HbA1c = hemoglobin A1c.

Table 10. Effect of Berries on Dietary Intake
Nonsmoker
Smoker
Smoker +
Control
Control
Blackberries
(n=14)
(n=11)
(n=6)
Mean
SEM
Mean
SEM
Mean
SEM
%
%
%
%
%
%
Energy
3.91
8.45
7.50
9.13
19.20
12.91
Total Fat
8.00
10.41
7.38
11.25
17.37
15.91
Saturated Fat
2.42
11.59
8.35
12.51
14.45
17.70
PUFA
17.45
14.38
1.93
15.53
28.00
21.96
MUFA
12.06
11.39 13.11
12.30
16.53
17.40
Cholesterol
-9.50
10.56
3.71
11.41
12.18
16.14
Sodium
-12.96 17.60 -39.56 19.84 -11.25 26.88
Potassium
-2.93
14.67 -38.31 16.60
23.66
22.40
Carbohydrates
8.85
10.37 17.81
11.20
35.88
15.84
Total Fiber
8.42
24.74 18.87
26.72
49.30
37.79
Protein
-2.92
8.73
0.94
9.43
4.44
13.34

Smoker +
Blueberries
(n=13)
Mean SEM
%
%
1.57
8.77
-3.23 10.81
-6.01 12.02
10.74 14.92
-1.72 11.82
-5.67 10.96
-4.19 18.26
-18.89 15.22
18.14 10.76
80.96 25.67
-2.11 9.06

Data represents percent change from baseline. A positive value indicates an increase and a
negative value indicates a decrease. Kcal = kilocalories; MUFA = monounsaturated fatty acids;
PUFA = polyunsaturated fatty acids. One smoker control was eliminated due to extreme
outliers for energy, total fat, carbohydrates, and total fiber.
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FIGURES
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Bars represent mean ± SEM from baseline data. Groups of bars that do not share a common letter are
significantly different (p<0.05). TC = total cholesterol; LDL-C = low-density lipoprotein cholesterol;
HDL-C = high-density lipoprotein cholesterol.
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Data represents mean percent change ± SEM. TC = total cholesterol; LDL-C = low-density lipoprotein
cholesterol; HDL-C = high-density lipoprotein cholesterol.
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INFORMED CONSENT
Title: The Role of Antioxidant Rich Berries in Prevention of SmokingInduced Bone Loss in Postmenopausal Women
Investigator(s):
Dr. Latha Devareddy
Assistant Professor
Lydia K. Kaume M.S.
Graduate Research Assistant
Department of Food Science
Division of Agriculture
University of Arkansas
2615 N. Young Ave.
FDSC N-216
479-575-4474
ldevared@uark.edu

Dr. Ro Di Brezzo
Human Performance
Laboratory College of
Education and Health
Professions Dept. of
Health, Kinesiology,
Recreation, and Dance
155 Stadium Drive HPER 321
479-575-6762
hpl@uark.edu

Rosemary Ruff, Director
Research & Sponsored
Programs
Research Compliance
University of Arkansas
120 Ozark Hall
Fayetteville, AR 72701
479-575-3845
rruff@uark.edu

Description: This is a research study with two primary objectives:
1) To evaluate the extent to which smoking aggravates bone loss in postmenopausal women,
and
2) Determine the role of antioxidant-rich berries such as blueberries and black berries in
prevention of this smoking-induced bone loss. The specific aims of the study are as follows:
Aim 1: To determine the extent to which smoking aggravates postmenopausal bone loss and
to assess the bone protective effects of blueberries and blackberries by measuring:
(a) Bone mineral density and bone mineral content of lumbar spine (L1-L4), whole body,
hip, and forearm
(b) Two biomarkers of bone formation (serum bone-specific alkaline phosphatase, ALP,
BSAP and osteocalcin, OC) and bone resorption (urinary deoxypyridinoline, Dpd and helical
peptide, HP).
Aim 2:
To identify potential modes by which these dried fruits modulate bone
metabolism by assessing:
(a) urinary calcium and phosphorus excretion
(b) serum and urinary F2-isoprostanes as well as other serum assays reflective of
antioxidant properties including superoxide dismutase, glutathione peroxidase, and
glutathione reductase.
As a participant in this study, you will fill out a quick Food Frequency Questionnaire (FFQ) to
help assess nutrition indices known to influence skeletal mass. These include dietary intake of
minerals such as calcium, magnesium, and boron, vitamins D and K, protein, and fiber as well as
relevant medical history and lifestyle variables. You may be recruited for the study if you are
postmenopausal woman with mild to moderate bone loss as will be determined by your bone
scan using the dual energy x-ray absorptiometry (DEXA). For the scan, you will be asked to lie
still on the DEXA table while the DEXA machine moves over you. This painless procedure is
simple, non-invasive and takes about 15 minutes to complete. The amount of radiation used by
the DEXA machine is about one eighth what you would receive from a chest x-ray. You will
then be assigned to one of the four treatment groups.
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These groups will be
I.
Non-smoking controls,
II.
Postmenopausal women who smoke daily,
III.
Postmenopausal women who smoke daily - assigned to eat 45 grams of dried
blueberries and
IV.
Postmenopausal women who daily - assigned to eat 45 grams of dried blackberries.
The duration of treatment will be for a period of nine months, a period sufficient to see
changes in bone mineral density (BMD) and bone mineral content (BMC). After this period,
your BMD and BMC will be assessed again using the DEXA machine. Fasting venous blood (20
ml, which is approximately 4 teaspoons) will be drawn for serum analyses will be collected
between 8:00-10:00 AM by a phlebotomist on designated dates at baseline, 3, 6, and 9, months.
You will also be instructed on how to collect second void urine samples on the same dates
before your visit to the department at baseline, 3, 6, and 9.
Duration of Involvement: Approximately 9 months
Number of participants: Approximately 60 postmenopausal women will participate in
this study.
Risks and Benefits: A small risk associated with the use of the DEXA machine is the
exposure to a small amount of ionizing radiation which is not known to have side effects and no
radiation remains in a patient's body after examination. The amount received during a DEXA
test is about the same as six (6) days of normal background radiation in Northwest Arkansas.
The great benefits include: free accurate and vital health information from the DEXA bone
density testing. This is the most accurate method available for the diagnosis of osteoporosis and
is also considered an accurate estimator of fracture risk. The risk associate with blood is
bruising. Blood will be drawn by a certified phlebotomist who will strictly follow the protocol.
Bruising can be prevented by keeping pressure on the site for several minutes after the needle
is withdrawn without bending their elbow.
Voluntary Participation: Participation in the research project is voluntary. You are free
to deny or withdraw from the study at any time if you so desire. Withdrawing from the study
or not participating will have no repercussions.
Removal from the Research Project: The principal investigator (P.I) or the sponsor
may also remove you from the project at any time and for any reason. Based on the
assessment of the P.I., some of the reasons that you might be removed from the project are,
but are not limited to the following:
• If you are not following instructions of your P.I. or her assistants
• If the study is terminated or
• For any reason at the discretion of the investigator
If you are removed from the project for any reason, your P.I. will ask you to have a final
evaluation. This evaluation could include any of the assessments/tests previously mentioned in
this document and any other procedures that the project P.I. feels are medically necessary.
You may also be asked questions about your experience with the project.
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Confidentiality: You will be assigned a code number, and this will be the only information
used for tracking purposes. Your testing information will be accessed only by persons directly
involved in the testing and will be stored in a locking filing cabinet. If your bone density score is
greater than 1.5 standard deviations below the norm for your age, gender, and race, you will be
alerted to address the risk for osteoporosis. Any other information used in this study will be
reported as group data without identifying information.
Compensation: US $ 25.00 per visit. If you develop health problems during the course of
the study, University of Arkansas will not provide compensation and will not provide medical
treatment without charge for any medical charges as a result of this research investigation.
Inclusion Criteria: Healthy women 1 to 5 years postmenopausal, whose lumbar spine BMD
t-score is between 0.5 and 2 SD below the mean, and not on HRT and/or other
pharmacological agents known to affect bone, will be enrolled in this proposed study. The
subjects will be postmenopausal women (i.e. follicle stimulating hormone; FSH >40 IU/mL) who
have not been on HRT or other osteoporosis related medications for at least six months prior
to the initiation of the study. Subjects who meet the inclusion criteria will be considered for the
study regardless of ethnicity and race.
Exclusion Criteria: The subjects who will be recruited for the study should not be receiving
endocrine (e.g., prednisone, other glucocorticoids) or neuroactive (e.g. dilantin, phenobarbital)
drugs or any drugs known to influence bone and calcium metabolism. Women whose BMD tscore at any site falls below 2.5 SD of the mean will be excluded from the study and referred to
their primary care physician. Furthermore, subjects treated with calcitonin, bisphosphonates,
raloxifene, sodium fluoride, anabolic agents, e.g. PTH and growth hormone, or steroids for less
than 6 months prior to the start of the study will be excluded. In addition, subjects with
metabolic bone disease, renal disease, a history of urolithiasis, cancer, cardiovascular disease,
diabetes mellitus, respiratory disease, gastrointestinal disease, liver disease, or other chronic
diseases will be excluded. Women with endometriosis, pelvic inflammatory disease, endometrial
polyps, and significant leiomyomata uteri will also be excluded from the study. Also women
who regularly consume blueberries or blackberries will not be accepted into the study.
Right to Withdraw: You are free to refuse to participate in the study and to withdraw at
any time. Your decision to withdraw will bring no penalty to you.
Who do I call if I have questions?
The study: Dr. Latha Devareddy at 479-575-4474
A study-related injury: Dr. Latha Devareddy at 479-575-4474
My rights as a person in the study: Washington Regional Medical Center Institutional
Review Board at 1125 N. College Ave, Fayetteville, AR 72703 (479) 713-7667 or (479) 4631000.
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Informed Consent: I, ____________________________________________, have
read the description of this program, including the purpose of the program, the procedures to
be used, the potential risks and side effects, the confidentiality, as well as the option to
withdraw from the program at any time. The investigator has explained each of these items to
me. The investigator has answered all of my questions regarding the program, and I understand
what is involved. My signature below indicates that I freely agree to participate in this program
and that I have received a copy of this agreement if desired from the investigator.
I will receive a copy of this signed consent if desired.
Signature:
By signing this consent form, I have not waived any of the legal rights, which I otherwise would
have as a participant in a research study
_______________________

________________________

_________

Participant’s Signature

Participant’s Printed Name

Date

_______________________

________________________

_________

Legal Representative Signature
(If necessary)

Legal Representative Printed Name

Date

IF SIGNED BY A PERSONAL REPRESENTATIVE OF THE INDIVIDUAL, DESCRIBE THE
REPRESENTATIVE’S LEGAL AUTHORITY TO ACT ON BEHALF OF THE INDIVIDUAL (e.g.
father):
_________________________________________________________________
_________________________________________________________________

________________________

________________________

___________

Person Obtaining Consent Signature

Obtaining Consent Printed Name

Date
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Subject ID: ____________________
Interviewer: ____________________

Date______________

HEALTH AND MEDICAL HISTORY QUESTIONNAIRE
Age________ Height_______ Weight________ BMI__________
I. Medical History
A. Skeletal Health
Personal history of skeletal disorders:
1. Not known ___________________
2. Yes: uncontrolled ________________
3. Yes: Medications _________________
4. Yes: Exercise program ___________________
5. Yes: Modified diet ________________
6. Yes: Surgery __________
7. Yes: Combined program __________
Give details _______________________________________________________
Type of Medication(s)_______________________________________________
Current dosage _________________ Years taken _________________________
How does this condition affect your activity?
Family history of skeletal disorders:
1.
2.
3.
4.
5.

None _____
One parent _____
Both parents _____
One close relative _____
More than one close relative _____

Relative(s) _______________________________________________
Comments: ______________________________________________

B. Cardiovascular Function
Personal history of cardiovascular disease:
1.
2.
3.
4.
5.
6.

Not known ___________________
Yes: uncontrolled ________________
Yes: Medications _________________
Yes: Exercise program ___________________
Yes: Modified diet ________________
Yes: Surgery __________
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7. Yes: Combined program __________
Give details _______________________________________________________
Type of Medication(s)_______________________________________________
Current dosage _________________ Years taken _________________________
How does this condition affect your activity?
Family history of cardiovascular disease:
1.
2.
3.
4.
5.

None _____
One parent _____
Both parents _____
One close relative _____
More than one close relative _____

Relative(s) _______________________________________________
Comments: ______________________________________________
C. Hypertension
1. None known ___________________
2. Yes: uncontrolled ________________
3. Yes: Medications _________________
4. Yes: Exercise program ___________________
5. Yes: Modified diet ________________
6. Yes: Yes: combined program__________
7. Most recent blood pressure __________
Explain_______________________________________________________
Type of Medication(s)_______________________________________________
Current dosage _________________ Years taken _________________________
Ever taken thiazide diuretics? ____________
D. Diabetes
1. No record or indication _____
2. In past, but not now _____
3. Yes, well controlled _____
4. Yes, not controlled _____
Explain ____________________________________________________
Type of Medication(s)_________________________________________
Current dosage _____________________Years taken________________
How does this condition affect your activity? _______________________
E. Gastrointestinal/Digestive Problems
1. No record or indication _____
2. In past, but not now _____
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3. Yes, well controlled _____
4. Yes, not controlled _____
Explain ____________________________________________________
Type of Medication(s)_________________________________________
Current dosage _____________________Years taken________________
Ever taken steroids (i.e., prednisone)? ______________________
Currently taking antacids? _______________________________
How does this condition affect your activity? ________________
F. Liver Disease/ Problems
1. No record or indication _____
2. In past, but not now _____
3. Yes, well controlled _____
4. Yes, not controlled _____
Explain ____________________________________________________
Type of Medication(s)_________________________________________
Current dosage _____________________Years taken________________
How does this condition affect your activity? _______________________

G. Respiratory Problems
1. No record or indication _____
2. In past, but not now _____
3. Yes, well controlled _____
4. Yes, not controlled _____
Explain ____________________________________________________
Type of Medication(s)_________________________________________
Current dosage _____________________Years taken________________
How does this condition affect your activity? _______________________
H. Thyroid Disorder
1. No record or indication _____
2. In past, but not now _____
Hyper? _____
Hypo? ___
Explain ____________________________________________________
Type of Medication(s)_________________________________________
Ever taken thyroid hormones (i.e., Synthroid)? _____
I. Reproductive history
LMP_____________; No. of children______________
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II. Medication or Drug Use
A. Previous or Present Use of Any of the Following (Specify):
1. Anabolic steroids _____________
2. Corticosteroids or glucocorticoids _____prednisone _____
3. Thiazide diuretics _____ Other diuretics _____
4. Vitamin D
5. Medications for bone:
Fosamax: ___________________________
Evista (Roloxaphin): ___________________
Miacalcin (Calcitonin): _________________
Teriparatide (Forteo):___________________
6. Others:
___________________________________________________
___________________________________________________
___________________________________________________
B. Previous or Present Use of Alcoholic Beverages (Beer, wine, hard liquor)
Please indicate:
Frequency of intake (Times/week or times/month): _____
Number of servings at a sitting: _____
Number of years of use: _____
C. Estrogen or Hormone Replacement (ERT or HRT)
1. Never ___ move along to section D.
2. Yes, in past ___ at what age? ___ & How long _____
D. Currently /previously a smoker?
______If yes, number of cigarettes per day____________
III. Physical Activity
A. Occupational Intensity (respond to 1, 2, 3, or 4):
1. Majority of time: Sitting ___ Standing ___ Walking ___
2. Equal amount of time:
Sitting and Standing ___
Walking and Sitting ___
Standing and Walking ___
3. Combination: Sitting, Standing, and Walking ___
4. Much of time: Lifting & Carrying
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Date: ______________

ID: ______ 0M 3M 6M 9M

Interviewer: _____________

Vitamin and Mineral Supplement(s)
1. Do you take any vitamin or mineral supplement(s)?

Yes _____

No _____

2. If yes, please list all names of vitamins or mineral supplements and how often you take the
supplement(s)?
Name _____________________________
Name _____________________________
Name _____________________________
Name _____________________________
Name _____________________________
Name _____________________________
Name _____________________________

How often?
How often?
How often?
How often?
How often?
How often?
How often?

_____ per day
_____ per day
_____ per day
_____ per day
_____ per day
_____ per day
_____ per day

_____ per week
_____ per week
_____ per week
_____ per week
_____ per week
_____ per week
_____ per week

Food Frequency Questionnaire
This questionnaire asks you about your consumption of foods and beverages over the past week,
which includes the time from exactly one week ago until the last meal you had before you fill out
this questionnaire. The quantity column is the amount of food/beverage and the interval is how
often (day/week).
Description

Amnt

Unit

1.00

sl.

1.00

svg.

0.50

item

5.00

item

5.00
1.00
1.00
1.00
0.50

item
item
item
svg.
c.

0.50

c.

0.75
0.75
0.50
0.50

c.
c.
c.
c.

Quantity

Day/Week

Breads Cereals and Grain Products

Whole grain breads (whole wheat, rye, pumpernickel)
White breads (french - 1 slice, burger/hot dog bun-1/2
item)
English muffin, bagel, pita bread
Whole grain crackers: Triscuits, Wheat Thins, etc. (4-6
each)
Other crackers: Saltines, Ritz, etc. (4-6 each)
Tortilla, corn, 6 inch diameter (medium)
Muffins
Pancakes (2), waffles (1-7 inch diameter)
Whole grain hot cereal: rolled oats, rolled wheat
Instant or quick hot cereal: cream of wheat, cream of
rice
Cold cereals: shredded wheat, raisin bran, or bran flakes
Cold cereals: Frosted Flakes, Sugar Smacks, etc.
Rice, cooked
Pasta, cooked
Fruits and Juices
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Apple or pear, fresh, medium
Banana, medium
Orange (1 item) or grapefruit (1/2 item)
Peach (1), nectarine (1/2) or apricots (2)
Berries (in season)
Cantaloupe, medium (in season)
Other melon (watermelon, honeydew, casaba)
Pineapple, fresh
Dried fruits: raisins (2 tbsp), dates (2), prunes (2), dried
apricots (4)
Canned fruit or frozen fruit
Orange or grapefruit juice
Tomato juice or vegetable juice
Other juices: apple, grape, pineapple, or cranberry
Fruit drinks: lemonade, punch, Koolaid

1.00
1.00
1.00
1.00
0.75
0.25
1.00
0.50

item
item
svg.
svg.
c.
c.
c.
c.

0.25

c.

0.50
0.50
0.50
0.50
0.50

c.
c.
c.
c.
c.

1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00

T.
T.
T.
T.
t.
t.
T.
T.
T.
T.
T.
T.

1.00
1.00
1.00
1.00
1.00
1.00
0.50

c.
c.
c.
c.
oz.
oz.
c.

1.00
0.50
0.50
1.00

c.
c.
c.
item

Fats and Oils

Vegetable oils: corn, safflower, soy, etc
Olive oil
Shortening
Lard
Margarine
Butter
Mayonnaise
Regular salad dressings
Low-calorie dressings
Sour cream
Cream cheese
Half & Half, table cream
Milk, Yogurt and Cheeses

Skim milk or low fat milk
Whole milk
Chocolate milk
Yogurt
Cheese: cheddar, Colby, American, Monterey Jack, etc.
Other cheeses: Swiss, mozzarella, ricotta, string, etc.
Cottage cheese
Vegetables

Salads: lettuce, celery, green peppers, onions
Dark green leafy vegetables, raw or cooked
Carrots, raw or cooked
Tomatoes, fresh, medium
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Starchy vegetables, cooked: corn, peas, mixed vegetables
Other vegetables, cooked: green beans, beets, zucchini
Cauliflower, broccoli, brussel sprouts, cabbage
Winter squash, cooked: acron, butternut, hubbard
White potato, baked, broiled, or mashed
Sweet potatoes or yams, cooked

0.50
0.50
0.50
0.50
1.00
0.50

c.
c.
c.
c.
item
c.

12.00
12.00
12.00
12.00
8.00
8.00
1.00
12.00
4.00
1.50

fl.oz.
fl.oz.
fl.oz.
fl.oz.
fl.oz.
fl.oz.
c.
fl.oz.
fl.oz.
fl.oz.

1.00
0.25
1.00
3.00
3.00
3.00
3.00
3.00
3.00
3.00
3.00

c.
c.
T.
oz.
oz.
oz.
oz.
oz.
oz.
oz.
oz.

3.00

oz.

3.00
1.00
0.25
1.00
1.00

oz.
item
c.
item
item

2.00
1.00
1.00
1.00

item
item
item
sl.

Beverages

Cola drinks (1 can = 12 fl. oz)
Diet cola drinks (1 can = 12 fl. oz)
Non-cola drinks: 7-Up, Sprite, Slice, etc. (1 can/12 fl. oz)
Diet non-cola drinks (1 can = 12 fl. oz)
Coffee or tea (1 cup = 8 fl. oz)
Decaffeinated coffee or teas: Sanka, herbal tea, etc.
Hot chocolate or cocoa
Beer (1 can = 12 fl. oz)
Wine, dry or table (red, white, or blush)
Liquor: vokda, whiskey, gin, rum, etc.
Protein Foods

Legumes: lentils, pinto beans, navy beans, cooked
Nuts and seeds: peanuts, almonds, sunflower seeds, etc.
Peanut butter, nut butters
Tofu or other meat substitutes
Beef: rib roast, steak, pot roast, veal, etc.
Beef, ground, cooked
Pork: chops, roast, ham
Lamb: chops, roast
Poultry: chicken, turkey, duck
Fish, canned with oil: tuna, sardines
Tuna, water packed
Fish, fresh or frozen, no breading: trout, halibut, sole,
etc.
Shellfish: shrimp, scallops, lobster, clams
Eggs, whole, large
Egg substitutes or egg whites
Lunch meats: bologna, salami, etc.
Frankfurters or sausage link (4 in x 1 1/8 in)
Desserts and Sweets

Cookies: chocolate chip, oatmeal, peanut butter, etc.
Brownies, 2 in.
Doughnut or sweet roll
Cake, 1/12 of 9 in.
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Granola bars (1 item) or granola (1/2 cup)
Pie, 1/8 of whole pie
Gelatin, flavored
Pudding or custard
Ice Cream
Ice Milk
Sherbet
Candy bar, chocolate bar (1 bar), M&Ms (1 pkg.)
Hard candy, gum drops, Lifesavers

1.00
1.00
0.50
0.50
0.50
0.50
0.50
1.00
1.00

item
sl.
c.
c.
c.
c.
c.
item
item

1.00
1.00
1.00
2.00
2.00
1.00
1.00
0.50
1.00
5.00
1.00
0.25
1.00
1.00
1.00
1.00

sl.
item
item
sl.
c.
oz.
T.
c.
T.
item
T.
c.
c.
c.
item
T.

Miscellaneous Foods

Fast food - pizza
Fast food - hamburger or cheeseburger
Fast food - burrito or taco
Bacon
Popcorn, popped
Potato chips, corn chips, tortilla chips
Catsup or chili sauce
Tomato based sauce (spaghetti sauce)
Pickles or pickle relish (1 Tbsp)
Olives
Sauces: soy sauce, steak sauce, barbeque sauce
Brown gravy, giblet gravy, or white sauce
Soups, vegetable or noodle type
Soups, cream
Chewing gum
Sugar, honey, jam, jelly, syrups

Can you think of any other food or drink that you had in the past week that was not on this form?
If so, what was it? What was the amount? How many times did you have this in the past week?
Food _______________________________________________
Amount _________________________ How often? ________ per day, ________ per week
Food _______________________________________________
Amount _________________________ How often? ________ per day, ________ per week
Food _______________________________________________
Amount _________________________ How often? ________ per day, ________ per week
Food _______________________________________________
Amount _________________________ How often? ________ per day, ________ per week
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